Carbapenemase Inhibitors: Updates on Developments in 2021

• Authors: Maroun Bon Zerdan, SUNY Upstate Medical University; Sally Al Hassan, American University of Beirut Medical Center; Waleed Shaker, New Cross Hospital; Rayan E Hajjar, Thomas Jefferson University; Sabine Allam, University of Balamand; Morgan Bou Zerdan, American University of Beirut; Amal Naji, Emory University; Nabil Zeineddine, SUNY Upstate Medical University
• Journal Title: Journal of Clinical Medicine Research
• Volume: Volume 14, Number 7
• Publisher: Elmer Press Inc. | 2022-07-01, Pages 251-259
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.14740/jocmr4764
• Subjects: Health Sciences, Medicine and Surgery; Health Sciences, Pathology; Biology, Anatomy
• Keywords: Carbapenem resistance; Carbapenemase inhibitors; Pathogens

Abstract

Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avi-bactam, relebactam and vaborbactam, would address this resistance. Our review summarizes the latest developments related to carbap-enemase inhibitors synthesized to date, as well as their spectrum of activity and their current stage of development. A particular focus will be on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens. These new combinations mark a critical step forward the fight against antimicrobial resistance.